Last reviewed · How we verify
HGP0412 capsule
HGP0412 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
HGP0412 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (Phase 3 development).
At a glance
| Generic name | HGP0412 capsule |
|---|---|
| Also known as | Tamsulosin HCl 0.2mg |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HGP0412 targets FGFR, a receptor tyrosine kinase frequently dysregulated in various solid tumors through gene amplification, mutation, or translocation. By inhibiting FGFR signaling, the drug suppresses tumor cell proliferation and survival pathways dependent on FGF/FGFR axis activation. This mechanism is particularly relevant in cancers with FGFR alterations, including certain gastric, bladder, and other epithelial malignancies.
Approved indications
- FGFR-altered solid tumors (Phase 3 development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HGP0412 capsule CI brief — competitive landscape report
- HGP0412 capsule updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI